Myelodysplastic Syndromes (MDS)

Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

Background: The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients' health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients' HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible.

TP53 Mutation Status Possesses Prognostic Implications in MDS

Original Publication Date
Article Source
External Web Content
Patients with myelodysplastic syndromes (MDS) who have biallelic TP53 have worse outcomes, such as treatment-resistant disease, rapid disease progression, and low overall survival, versus those with monoallelic mutations, according to results from a study published in Nature…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.